Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Patients across Wisconsin — from Abbotsford to smaller communities — are transforming their lives with FDA-approved GLP-1 medications through licensed telehealth. For many, it is the breakthrough they have been waiting for after years of struggling with traditional approaches. Our WI-licensed physicians evaluate your eligibility and build a personalized GLP-1 treatment plan designed for maximum results.
The transformation is real and measurable. Clinical trials demonstrate that patients using semaglutide (Ozempic, Wegovy) lose an average of 15% of body weight, while tirzepatide (Mounjaro, Zepbound) produces up to 22% average weight reduction over approximately 72 weeks — along with dramatic improvements in cardiovascular health, blood sugar, energy, and quality of life.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Wisconsin supports patients seeking transformative weight management through licensed telehealth. All providers hold active WI medical licenses and follow evidence-based treatment protocols for GLP-1 prescribing — ensuring your transformation is built on a solid medical foundation.
Select your Wisconsin city to begin your health transformation. Licensed GLP-1 specialists are serving patients in every corner of the state.
Three randomized controlled trials published in the New England Journal of Medicine establish the evidence base for FDA-approved GLP-1 medications:
Wisconsin authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in Wisconsin.
Life-changing GLP-1 results extend beyond Wisconsin — our transformation network covers all neighboring states and all 50 states nationwide.
Life-changing GLP-1 results are happening in the largest cities across the United States. Select a city to begin your transformation.
Local weight loss and GLP-1 providers serving the Wisconsin area, based on Google Business listings.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Wisconsin patients using semaglutide (Wegovy) achieve an average of 15% body weight loss over 68 weeks. Those on tirzepatide (Zepbound) see up to 22% average weight reduction over 72 weeks. Beyond the scale, patients report dramatic improvements in energy, blood pressure, blood sugar, and overall quality of life.
Most Wisconsin patients notice reduced appetite within the first 1-2 weeks. Visible weight loss typically begins within the first month and accelerates with dose titration. The most significant transformation typically occurs between months 3-6, with continued improvement throughout treatment.
Yes. GLP-1 medications work through hormonal mechanisms that address the biological roots of excess weight — not just behavior. Many Wisconsin patients who struggled for years with conventional approaches achieve breakthrough transformation with GLP-1 because it directly addresses appetite regulation and metabolic dysfunction.
GLP-1 transformation goes beyond weight loss. Wisconsin patients experience measurable improvements in HbA1c, systolic blood pressure, triglycerides, LDL cholesterol, joint pain, sleep quality, and cardiovascular risk. The SELECT trial showed semaglutide reduced major cardiac events by 20% in at-risk patients.
Clinical evidence shows weight is often maintained during treatment. To sustain transformation after discontinuation, physicians recommend pairing GLP-1 therapy with lifestyle changes. Wisconsin physicians offer ongoing support and maintenance dosing options to help patients preserve their results long-term.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
